More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.20B
EPS
-6.05
P/E ratio
--
Price to sales
129.24
Dividend yield
--
Beta
0.456958
Previous close
$53.17
Today's open
$52.68
Day's range
$51.37 - $52.98
52 week range
$51.37 - $88.31
show more
CEO
Robert I. Blum
Employees
673
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
139303351
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
Cytokinetics NASDAQ: CYTK executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy.
MarketBeat • Nov 17, 2026

Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
Cytokinetics NASDAQ: CYTK executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of aficamten, the drug's active ingredient.
MarketBeat • Nov 16, 2026

Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol
GlobeNewsWire • Nov 16, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 13, 2026 it granted stock options to purchase an aggregate of 64,110 shares of common stock and 42,496 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in October and November 2026 as a material inducement to their employment.
GlobeNewsWire • Nov 16, 2026

Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten
GlobeNewsWire • Nov 9, 2026

Cytokinetics Q3 Earnings Call Highlights
Cytokinetics NASDAQ: CYTK reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand the treatment's use.
MarketBeat • Nov 5, 2026

Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026.
GlobeNewsWire • Nov 4, 2026

Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.54 per share a year ago.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cytokinetics Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.